![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/twitter.png)
![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/Logo_LinkedIn_round.png)
![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/youtube.png)
![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/flickr.png)
The Supplementary Protection Certificate (SPC) Manufacturing Waiver Regulation is applicable since 2 July 2022. The SPC Waiver has been introduced with the objective to remove the competitive disadvantage that European manufacturers of generic and biosimilar medicines are facing vis-à-vis third countries’ manufacturers, which can start manufacturing generics and biosimilars earlier due to shorter IP protection periods.